CLNN Clene Inc.

Clene is revolutionizing the treatment of neurodegenerative disease with an innovative nanotherapeutic platform to generate first-in-class elemental nanomedicines designed to optimize neurorepair and health through energy-enhancing bioenergetic catalysis.

$7.29  +0.31 (4.44%)
As of 05/14/2021 15:56:55 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/28/2020
Outstanding shares:  59,574,382
Average volume:  138,584
Market cap:   $415,829,186
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    185634102
Valuation   (See tab for details)
PE ratio:   -9.74
PB ratio:   -12.05
PS ratio:   0.00
Return on equity:   121.12%
Net income %:   -15,440.64%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy